- Record: found
- Abstract: not found
- Article: not found
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial
Yelena Y Janjigian ,
Kohei Shitara ,
Markus Moehler ,
Marcelo Garrido ,
Pamela Salman ,
Lin Shen ,
Lucjan Wyrwicz ,
Kensei Yamaguchi ,
Tomasz Skoczylas ,
Arinilda Campos Bragagnoli ,
Tianshu Liu ,
Michael Schenker ,
Patricio Yanez ,
Mustapha Tehfe ,
Ruben Kowalyszyn ,
Michalis V Karamouzis ,
Ricardo Bruges ,
Thomas Zander ,
Roberto Pazo-Cid ,
Erika Hitre ,
Kynan Feeney ,
James M Cleary ,
Valerie Poulart ,
Dana Cullen ,
Ming Lei ,
Hong Xiao ,
Kaoru Kondo ,
Mingshun Li ,
Jaffer A Ajani
June 2021
June 2021
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
<p class="first" id="d7384884e475">First-line chemotherapy for advanced or metastatic
human epidermal growth factor receptor
2 (HER2)-negative gastric or gastro-oesophageal junction adenocarcinoma has a median
overall survival (OS) of less than 1 year. We aimed to evaluate first-line programmed
cell death (PD)-1 inhibitor-based therapies in gastric, gastro-oesophageal junction,
and oesophageal adenocarcinoma. We report the first results for nivolumab plus chemotherapy
versus chemotherapy alone.
</p>